Download PowerPoint

National R&D Oncology Consortium
PI: J. Tímár MD PhD
National Institute of Oncology
Rath Gy 7-9, Budapest,H-1122 Hungary
Cancer morbidity and mortality’1999, Hungary
female
MT (15000)
MB
1. breast
2. colorectal
3. lung
4. stomach
5. pancreas
6. leukemia
7. ovary
8. cervix
9. liver
10.uterus
1. breast
2. colorectal
3. lung
4. skin
5. cervix
6. uterus
7. stomach
8. ovary
9. leukemia
10.pancreas
male
MT (19000)
MB
1. lung
2. colorectal
3. head and neck
4. prostate
5. stomach
6. pancreas
7. leukemia
8. bladder
9. liver
10.kidney
1. lung
2. colorectal
3. head and neck
4. prostate
5. skin
6. bladder
7. stomach
8. kidney
9. leukemia
10.pancreas
National Oncology
R&D Conzorcium (Hungary)
•
•
•
•
•
National Institute of Neurosurgery
National Institute of Pulmonology
National Institute of Epidemiology
Department of Pediatrics, Debrecen U.
Department of Immunology and
Biotechnology, Pécs University
• 1st Institute of Pathology & Experimental
Cancer Research, Semmelweis
University, Budapest
National institute of Oncology
• Department of Oncotherapy, Szeged
University
• Institute of Biotechnology, Bay Z.
Fundation, Szeged
• National Institute of Rabiobiology
• AstraZeneca Hungary
• Aventis Pharma Hungary
• Béres Co. Hungary
• Byk-Gulden
• Janssen-Cilag, Johnson and Johnson
• Pannonpark Ltd
• Pharmacia Hungary
• Bristol-Myers-Squibb Hungary
Cancer types to be investigated
•
•
•
•
•
•
•
•
•
Breast ca.
Lung ca.
Colorectal ca.
Head and neck ca.
Cervical ca.
Ovarian ca.
Malignant melanoma
Soft tissue sarcoma
Pediatric cancers: acute leukemia
neuroblastoma
nephroblastoma
• glioblastoma
Methodology
•
•
•
•
•
•
•
Laser-microdissection
Global genome analysis
DNA microarry design, production
real time quantitatív PCR
antibody design and production
protein-chip technology
in situ hibridization
Laser-microdissection
DNS
RNS
protein
Mutational analysis
Breast cancer
T
GAPDH
MAM
HER-2
TOPT II
V
N
Quantitative PCR
10x
20x
40x
80x
160x
2 kópia
1 kópia
Confocal Laser scanning microscopy
Screening and prevention
• Susceptibility:
drug metabolizing enzim-polymorphism
• Familiar breast, ovarian and colorectal cancer screening
• Genetical predisposition
• Neuroblastoma
Diagnostics
• Molecular diagnostics
soft tissue tumors
• Molecular staging
colorectal-, breast-, head and neck, ALL, NBL
• Prognostic pathology
colorectal-, breast-, lung-,head and neck,
melanoma
• Sensitivity to therapy:
drug metabolizing enzime polymorphism
drug-target identification
Novel therapeutic modalities
• Breast cancer:
Chemoprevention, New taxanes
combination of taxanes and Herceptin
• Melanoma:
Fragmin (lmw heparin)
• Cervical ca., rectal ca:
rhErythropoetin
• Glioblastoma:
gene therapy
Biotech products
• New method for blood detection in the stool
• WT1 oncogene probes, antibodies
• “Designer” oligo-chips for
differential diagnosis of soft tissue tumors
drug targets in breast-, head and neck cancers
Gene-map of tumor progression
drig metabolizing enzime polymorphism
• Design of protein chips for tumor progression
• cytokine-producing vestor systems
• geneticaly engenered human glioblastoma cell lines
1.Mol - epidemiol
2.Screening and prognosis
of colorectal cancer
OTFH
ANTSZ
SZBK
9.Gene therapy
of brain tumors
8.Molecular
pharmacology
OKTPI
SZE-OTK
SZBK
7.Tumor
Progression
3.Mol
diag
nos
tics
J. Tímár PI
4. Mol.diag.
6. Pediatric oncology
5.Mol.epidemiol. Diag.
of head and neck cancer
therapy of
breast
cc